Related by context. All words. (Click for frequent words.) 79 dosing schedules 77 dose regimens 74 dosing regimen 74 dosage regimens 72 tolerability 70 dose cohorts 70 dosage regimen 69 dosing 69 dose regimen 68 pharmacokinetic profiles 68 administered subcutaneously 67 ascending doses 67 mycophenolate mofetil 67 docetaxel Taxotere ® 67 placebo controlled studies 66 pharmacokinetic profile 66 SCH # 66 dosing intervals 66 nab paclitaxel 66 ritonavir boosted 66 pharmacodynamic profile 66 oral rivaroxaban 66 tolerability profile 65 ascending dose 65 pharmacokinetics PK 65 subcutaneous SC 65 mitoxantrone 65 tolerability profiles 65 mg doses 65 therapeutic regimens 65 chemotherapeutic regimens 65 subcutaneous injections 64 mg dose 64 intermittent dosing 64 subcutaneous dosing 64 galiximab 64 analgesic efficacy 64 intravenous dosing 64 pharmacodynamic properties 64 temsirolimus 64 teriflunomide 64 pomalidomide 64 #mg dose [001] 64 dosing frequency 64 pharmacokinetic parameters 64 pharmacodynamics PD 64 adalimumab 64 PREZISTA r 64 docetaxel chemotherapy 64 MIRCERA 64 dexamethasone Decadron 64 vicriviroc 64 forodesine 64 APTIVUS 64 tigecycline 64 ganetespib 63 pharmacokinetic properties 63 treatment regimens 63 CANCIDAS 63 administered orally 63 posaconazole 63 APTIVUS r 63 dosed orally 63 optimal dosing 63 BAY #-# 63 Mitoxantrone 63 platelet inhibitor 63 dosing cohorts 63 dose escalation 63 mcg dose 63 MYCAMINE 63 DAPT 63 sorafenib Nexavar 63 Panzem R NCD 63 pharmacokinetics 63 abacavir lamivudine 63 efficacy tolerability 63 fulvestrant 63 Traficet EN 63 ibandronate 63 active comparator 63 safety tolerability pharmacokinetics 63 chemotherapy regimens 63 sorafenib tablets 63 HCV SPRINT 63 tipranavir 63 insulin detemir 63 edoxaban 63 piperacillin tazobactam 62 oral dosing 62 lapatinib Tykerb 62 placebo controlled clinical 62 insulin degludec 62 secondary efficacy endpoints 62 pegfilgrastim 62 placebo controlled trials 62 LEXIVA r 62 primary hypercholesterolemia 62 LEP ETU 62 subcutaneous formulation 62 antiviral efficacy 62 GnRH agonists 62 maximally tolerated dose 62 FOLPI 62 pharmacodynamics 62 LY# [003] 62 subcutaneous dose 62 Pegasys ® 62 protease inhibitor PI 62 TNF inhibitor 62 esomeprazole 62 ancrod 62 nitazoxanide 62 AZILECT R 62 pharmacokinetic characteristics 62 INVEGA ® 62 cediranib 62 mitomycin 62 allopurinol 62 azacitidine 62 antihypertensive drugs 62 antiplatelet therapy 62 anti leukemic 62 tolvaptan 62 visilizumab 62 radezolid 62 oral deforolimus 62 etanercept 62 vandetanib 62 HAART regimens 62 telcagepant 62 dose escalation trial 62 mesalamine granules 62 immunomodulatory therapy 62 Doxil ® 62 placebo controlled clinical trials 61 mealtime insulin 61 monotherapy 61 bosentan 61 pharmacokinetic 61 enzastaurin 61 chlorambucil 61 GFT# 61 HAART regimen 61 NGX# 61 CR# vcMMAE 61 placebo controlled 61 decitabine 61 efficacy 61 antiplatelet agents 61 rFVIIa 61 Pemetrexed 61 nelfinavir 61 prucalopride 61 DU #b 61 mg RDEA# 61 subcutaneously administered 61 boosted protease inhibitor 61 superficial bladder cancer 61 mg QD 61 pharmacodynamic 61 Torisel 61 sunitinib 61 idraparinux 61 Sym# 61 fluticasone furoate 61 CorVue ™ 61 paclitaxel Taxol 61 bendamustine 61 peginterferon alfa 2b 61 docetaxel Taxotere 61 pertuzumab 61 PROMACTA 61 safety tolerability pharmacokinetic 61 phosphate binders 61 Chemophase 61 cilengitide 61 #mg/m# [001] 61 mTOR inhibitors 61 HCV RESPOND 2 61 Tekamlo 61 Carfilzomib 61 antiviral activity 61 Tarceva TM 61 lanthanum carbonate 61 Phase Ib 61 Phase 2b study 61 unfractionated heparin 61 sustained virologic response 61 carboplatin 61 solifenacin 61 subcutaneous doses 61 dose titration 61 Dasatinib 61 tacrolimus ointment 61 fluvastatin 61 Fludara 61 letrozole Femara 61 INTELENCE 61 interferon alfa 2b 61 IV bolus 61 GAMMAGARD 61 mcg doses 61 SPRYCEL 61 oral bioavailability 61 virologic failure 61 dose cohort 61 vorinostat 61 sunitinib malate 61 dosing cohort 61 pyridostigmine 61 vinorelbine 61 insulin glargine 61 PREZISTA rtv 61 NNRTIs 61 pegylated interferons 61 telbivudine 61 Bezielle 60 immunosuppressive regimens 60 viral kinetic 60 desvenlafaxine succinate 60 ISENTRESS 60 elvitegravir 60 bronchodilation 60 antihypertensive medications 60 efficacy endpoints 60 rt PA 60 tirofiban 60 TMC# [001] 60 Neulasta ® 60 AGILECT R 60 oral anticoagulant 60 tolerability pharmacokinetics 60 amphotericin B 60 pharmacodynamic effects 60 alfa 2a 60 REVLIMID lenalidomide 60 daunorubicin 60 cilostazol 60 ribavirin RBV 60 caspofungin 60 peginterferon alfa 2a 60 pegylated interferon alfa 2a 60 octreotide LAR 60 paclitaxel eluting stents 60 epoetin alfa 60 infusional 60 mg BID 60 axitinib 60 treprostinil 60 CA4P 60 intravenous IV infusion 60 pharmacokinetics pharmacodynamics 60 mapatumumab 60 irbesartan 60 Allovectin 7 ® 60 pramlintide metreleptin combination 60 antithrombotic 60 lopinavir ritonavir 60 TREDAPTIVE 60 mycophenolate mofetil MMF 60 melphalan prednisone 60 tolerated dose MTD 60 LEXIVA 60 glatiramer acetate 60 pharmacokinetic studies 60 latanoprost 60 TELINTRA 60 antiangiogenic agents 60 Hydroxyurea 60 preclinically 60 #mg doses [002] 60 uric acid lowering 60 PEGASYS ® 60 bisphosphonate therapy 60 rHuPH# 60 coadministration 60 double blinded placebo 60 bolus dose 60 tenofovir emtricitabine 60 flutamide 60 tiotropium 60 Phase Ib II 60 pramlintide 60 Phase 1b trial 60 bortezomib 60 topotecan 60 INCB# [002] 60 alpha blocker 60 standard chemotherapy regimens 60 tenofovir Viread 60 carboplatin paclitaxel 60 NOXAFIL 60 mg kg dose 60 subgroup analyzes 60 blinded randomized placebo controlled 60 intravesical 60 dacarbazine 60 etoposide 60 #mg/m# [002] 60 antiplatelet drugs 60 tanespimycin 60 mcg kg 60 rFIXFc 60 MEK inhibitors 60 telaprevir dosing 60 dosing interval 60 NEXIUM 60 infliximab 60 paliperidone palmitate 60 nucleoside analog 60 vidofludimus 60 dosages 60 bicifadine 60 amoxicillin clavulanate 60 PXD# 60 Laquinimod 60 zolmitriptan 60 Microplasmin 60 paricalcitol 60 pegylated interferon alfa 60 apremilast 60 delafloxacin 60 oral prodrug 60 inhibitor RG# 60 rivaroxaban 60 Dapagliflozin 60 alicaforsen enema 60 intravenous bisphosphonates 60 sirolimus 60 albinterferon alfa 2b 60 PEGylated interferon beta 1a 60 paclitaxel Taxol ® 60 FOLFIRI 60 cardiac toxicity 60 temozolomide 60 xanthine oxidase inhibitor 60 pharmacokinetic PK profile 59 dabigatran etexilate 59 timepoints 59 thromboembolic events 59 YONDELIS 59 tramadol acetaminophen 59 antiretroviral regimen 59 pharmacodynamic markers 59 fluorouracil 59 tacrolimus 59 β blockers 59 intramuscular injections 59 darunavir 59 Phase IIb trials 59 elotuzumab 59 interferon alfa 59 dasatinib 59 KAPIDEX 59 leucovorin 59 placebo controlled Phase 59 CUSTOM III 59 direct thrombin inhibitors 59 biodistribution 59 ketorolac 59 EVIZON 59 proton pump inhibitor PPI 59 docetaxel 59 μg dose 59 antihypertensive agents 59 dual antiplatelet therapy 59 exenatide 59 urate lowering 59 raltegravir 59 noninferiority 59 Copegus ribavirin 59 Diovan HCT 59 fondaparinux 59 lomitapide 59 immunosuppressive agents 59 IMGN# 59 tecarfarin 59 insulin lispro 59 TORISEL 59 #mg dose [003] 59 nonrandomized 59 q8h 59 PRISTIQ 59 Vidaza azacitidine 59 Taxotere ® 59 deferiprone 59 dose escalation study 59 CYT# 59 deferoxamine 59 sapacitabine 59 antiepileptic drugs AEDs 59 octreotide 59 aspirin clopidogrel 59 leflunomide 59 gemcitabine 59 clopidogrel Plavix 59 peginterferon alfa 2a #KD 59 DAVANAT 59 trials RCTs 59 riociguat 59 factorial design 59 beclomethasone dipropionate 59 TNF alpha inhibitor 59 imipenem 59 pimecrolimus 59 fluticasone salmeterol 59 stavudine d4T 59 SAPHRIS 59 CCR5 antagonist 59 olmesartan 59 steroid dexamethasone 59 combinability 59 certolizumab 59 peg interferon 59 pioglitazone 59 HGS# 59 REYATAZ R 59 thromboprophylaxis 59 antiemetics 59 Phase IIa trial 59 LIALDA 59 ribavirin therapy 59 oral iron chelator 59 ponatinib 59 interferon alfa 2a 59 virological failure 59 cannabinor 59 peg IFN 59 phase Ib 59 bevacizumab Avastin ® 59 antitumor activity 59 ARIKACE 59 neratinib 59 Phase III Clinical Trials 59 MMP inhibitors 59 chlorthalidone 59 pharmacokinetic PK 59 iniparib 59 oral formulation 59 tocilizumab 59 intravenously administered 59 mg/m2 dose 59 VAPRISOL 59 JANUVIA 59 valacyclovir 59 standard chemotherapy regimen 59 GnRH antagonist 59 plus ribavirin 59 INCB# [001] 59 integrase inhibitor 59 genotypic resistance 59 relapsing remitting multiple sclerosis 59 dose colchicine 59 Golimumab 59 angiogenesis inhibitor 59 basal insulin 59 ACTEMRA TM 59 CoFactor 59 cyclosporin 59 raloxifene Evista 59 dexpramipexole 59 antiarrhythmic drug 59 ZYVOX 59 randomized controlled clinical trials 59 glycopyrrolate 59 eltrombopag 59 Inhalation Solution 59 eptifibatide 59 viral kinetics 59 chemoradiotherapy 59 Azedra 59 PRTX 59 DermaVir Patch 59 intramuscular 59 LHRH antagonists 59 docetaxel Taxotere R 59 ceftriaxone 59 romiplostim 59 FOLFOX 59 ximelagatran 59 Peg IFN 59 virologic response 59 Rivaroxaban 59 paclitaxel cisplatin 59 ZD# [001] 59 alpha 2a 59 SRT# [003] 59 glufosfamide 59 bisphosphonate 59 teriparatide 59 regimens 59 custirsen 59 imatinib Gleevec 59 leukotriene receptor antagonist 59 budesonide formoterol 59 systemically administered 59 fosamprenavir 59 oral anticoagulants 59 FOSRENOL ® 58 Afatinib 58 PegIntron 58 trospium 58 #mg dose [002] 58 active moiety 58 eculizumab 58 PRADAXA 58 suppressive therapy 58 belinostat 58 recurrent GBM 58 NSTE ACS 58 topiramate Topamax 58 adjuvant therapies 58 entecavir 58 varespladib 58 RSD# oral 58 huN# DM1 58 REMINYL ® 58 Taxotere R 58 Phase 2b trial 58 Phase 2a trial 58 relapsing MS 58 QD dosing 58 sitagliptin 58 atazanavir 58 Omacetaxine mepesuccinate 58 Elitek 58 lipid lowering agents 58 AZOR 58 adipiplon 58 antithrombotics 58 RDEA# 58 oral alendronate 58 Protelos 58 Prograf ® 58 Tolerability 58 INFERGEN 58 TG# [003] 58 intravenous infusion 58 oral ridaforolimus 58 primary efficacy endpoints 58 phase IIa clinical 58 dalbavancin 58 SCIg 58 interferon ribavirin 58 otelixizumab 58 Aptivus 58 Capecitabine 58 continuous intravenous infusion 58 selegiline 58 Phase Ib study 58 epoetin 58 Pegasys peginterferon alfa 2a 58 sipuleucel T 58 favorable pharmacokinetic profile 58 calcineurin inhibitors 58 BoNTA 58 administered intranasally 58 Darunavir 58 rituximab Rituxan 58 Phase Ib clinical 58 REMICADE ® 58 KRAS status 58 pyrazinamide 58 pharmacodynamic parameters 58 Vfend 58 Femara letrozole 58 cyclophilin inhibitor 58 NATRECOR ® 58 tolterodine ER 58 ulimorelin 58 liposomal formulation 58 YERVOY 58 salmeterol fluticasone 58 itraconazole 58 DMARDs 58 MAGE A3 ASCI 58 antiplatelet therapies 58 darbepoetin alfa 58 anti angiogenic agents 58 Zavesca R 58 xenograft models 58 idarubicin 58 seliciclib 58 nevirapine Viramune 58 generation purine nucleoside 58 FOSRENOL R 58 Alocrest 58 levetiracetam 58 intravitreal injection 58 Cytoxan 58 ARCOXIA 58 lenalidomide dexamethasone 58 placebo controlled randomized 58 colorectal liver metastases 58 tolterodine 58 calcitonin 58 CTAP# Capsules 58 ritonavir boosting 58 Perforomist ™ Inhalation Solution 58 ixabepilone 58 VELCADE melphalan 58 pegylated interferon 58 rosuvastatin 58 Epoetin alfa 58 nucleoside reverse transcriptase inhibitor 58 antidiabetic drugs 58 antiviral therapy 58 latrepirdine 58 eprotirome 58 chemotherapies 58 valsartan 58 tezampanel 58 ustekinumab 58 liver biopsies 58 FASLODEX 58 KRN# 58 CBLC# 58 fibrinolytic 58 CIMZIA TM 58 anidulafungin 58 octreotide acetate 58 Exenatide 58 weekly subcutaneous injections 58 peginterferon 58 MGCD# [001] 58 FOLFOX4 58 Betaferon ® 58 Noxafil 58 celecoxib 58 safety tolerability 58 cyclophosphamide 58 thalidomide Thalomid 58 erlotinib Tarceva ® 58 Targretin 58 LEVADEX 58 rNAPc2 58 RRMS patients 58 ziprasidone 58 capsule formulation 58 sorafenib 58 LEUKINE 58 oral antidiabetic agents 58 anticoagulation therapy 58 pioglitazone Actos 58 isoniazid 58 non selective NSAIDs 58 liposomal amphotericin B 58 NVA# 58 Interferon alpha 58 JAK inhibitor 58 low dose cytarabine 58 chemotherapeutic agents 58 cytarabine 58 adjuvant therapy 58 Q#IR 58 hypofractionated 58 GP IIb IIIa inhibitors 58 gout flares 58 aldosterone antagonist 58 Tiotropium 58 miconazole 58 lipid lowering therapies 58 Anticalins 58 PEG Interferon lambda 58 Prograf R 58 levosimendan 58 metabolic parameters 58 Perforomist TM Inhalation Solution 58 panitumumab Vectibix 58 Asentar 58 tasimelteon 58 INVEGA R 58 TPI ASM8 58 Anti TNF 58 pharmacodynamic PD 58 alefacept 58 ceftazidime 58 Cloretazine 58 MoxDuo TM IR 58 pramipexole 58 multicenter randomized placebo controlled 58 alkylating agent 58 mixed dyslipidemia 58 venlafaxine Effexor 58 chemotherapy regimen 58 Vidofludimus 58 motesanib 58 fluconazole 58 GEM OS2 58 cinacalcet 58 odanacatib 58 warfarin therapy 58 Pegasys R 58 Rebif ® 58 proguanil 58 phase IIb clinical 58 PREOS 58 clodronate 58 hydroxychloroquine 58 ZOLINZA 58 NATRECOR R 58 INC# 58 stavudine 58 IMC A# 58 double blind placebo 58 rizatriptan 58 pharmacokinetic interactions 58 COPD exacerbations 58 DMARDS 58 serum concentrations 57 Tindamax R 57 concurrent chemoradiation 57 IIIa inhibitor 57 q#h 57 FTY# 57 milligram doses 57 plasma kallikrein inhibitor 57 RLY# 57 5-FU/LV 57 lopinavir r 57 antitumor efficacy 57 dose cytarabine 57 LPV r 57 alvimopan 57 REVLIMID ® 57 LMWH 57 voriconazole 57 randomized multicenter 57 cytotoxic agents 57 androgen suppression 57 antitumor effect 57 EXPAREL ™ 57 mesalamine 57 CINTREDEKIN BESUDOTOX 57 cidofovir 57 cariprazine 57 heavily pretreated patients 57 atherothrombotic events 57 anti coagulant therapy 57 epoetin beta 57 Aclidinium 57 TELCYTA 57 biologic therapy 57 ropinirole 57 Tamibarotene 57 plus dexamethasone 57 anakinra 57 deferasirox 57 AEGR 57 multicenter randomized 57 alteplase 57 TYGACIL 57 dose dose escalation 57 cangrelor 57 enfuvirtide 57 eniluracil 57 neurologic progression 57 Telintra 57 NRTI 57 antiepileptics 57 alvespimycin 57 placebo controlled Phase III 57 protease inhibitors PIs 57 SYMBICORT 57 candesartan cilexetil 57 inhalations twice 57 ATACAND 57 zonisamide SR 57 FIRMAGON 57 virological response 57 APOPTONE 57 pegylated IFN 57 Ozarelix 57 receptor tyrosine kinase inhibitor 57 cSSSI 57 rosuvastatin Crestor 57 CEQ# 57 clevidipine 57 refractory CLL 57 mesalazine 57 #mg QD [001] 57 INCB# [003] 57 6R BH4 57 mg/m2 57 budesonide foam 57 acting muscarinic antagonist 57 PRT# 57 LATUDA 57 OMS# 57 oral diclofenac 57 nebulization 57 IFN beta 57 intravesical instillation 57 estramustine 57 metastatic HRPC 57 ISTODAX 57 BRAF inhibitor 57 trastuzumab Herceptin ® 57 rilpivirine 57 molecular weight heparins 57 phase IIIb 57 thienopyridines 57 adalimumab Humira 57 Tekturna HCT 57 randomized #:#:# 57 anticancer therapies 57 clopidogrel 57 Symadex 57 intradermal injection 57 Dacogen injection 57 Phase 2a 57 lixisenatide 57 Vandetanib 57 Octreolin 57 maraviroc 57 Phase Ib clinical trials 57 PSN# [002] 57 antiplatelet medication 57 regorafenib 57 gemcitabine Gemzar 57 olanzapine Zyprexa 57 blind randomized placebo 57 MyVax R 57 ABC/3TC 57 pain palliation 57 adefovir 57 Carvedilol 57 tamsulosin 57 velafermin 57 antisense compounds 57 pioglitazone HCl 57 levothyroxine 57 budesonide 57 pegylated interferon alfa 2b 57 adecatumumab 57 mRCC 57 factor Xa inhibitor 57 bioavailability 57 montelukast 57 cabazitaxel 57 hour bronchodilation 57 HBeAg positive patients 57 gefitinib 57 randomized clinical 57 glucose lowering 57 LCP Tacro ™ 57 Phase IIIb clinical 57 Cimzia ® 57 hemodialysis patients 57 indibulin 57 PEG SN# 57 oral FTY# 57 intramuscularly 57 aripiprazole 57 5 FU 57 topical formulations 57 gemcitabine carboplatin 57 tasocitinib 57 nicardipine 57 Pharmacokinetics PK 57 ketoconazole 57 Pegylated Interferon 57 zileuton 57 Foradil Aerolizer 57 metformin sulfonylurea 57 Pegasys plus Copegus 57 oritavancin 57 pharmacodynamic endpoints 57 oral renin inhibitor 57 goserelin 57 abiraterone acetate 57 ruxolitinib 57 MoxDuo 57 nucleoside analogs 57 atazanavir ritonavir 57 interferon beta 1a 57 2 methoxyestradiol 57 ritonavir boosted atazanavir 57 prasugrel Effient 57 Telbivudine 57 prospective randomized controlled 57 SNRI 57 TDF FTC 57 nilotinib 57 Hyphanox 57 pregabalin Lyrica 57 pegylated liposomal doxorubicin 57 baminercept 57 IGIV 57 tofacitinib 57 endoscopic gastric ulcers 57 pimecrolimus cream 57 lipid lowering 57 surrogate endpoint 57 Amigal 57 synthetic progestin 57 FTY# fingolimod 57 topical NSAIDs 57 antiplatelet 57 divalproex sodium 57 buprenorphine naloxone 57 non inferiority 57 Combination therapy 57 oral bisphosphonates 57 leukotriene receptor antagonists 57 dalteparin 57 Events MACE 57 antiretroviral agents 57 PEGINTRON TM 57 phase IIb 57 ARB telmisartan 57 APTIVUS R 57 antiretroviral regimens 57 Dabigatran 57 telmisartan 57 virologic breakthrough 57 antibiotic regimens 57 intravesical therapy 57 BENICAR HCT 57 Dual Opioid 57 EOquin TM 57 MabCampath 57 gefitinib Iressa 57 Arixtra 57 SEROQUEL XR 57 Dabigatran etexilate 57 Rifampin 57 inhaled corticosteroid ICS 57 infliximab Remicade 57 Teriflunomide 57 NRTIs 57 cetuximab Erbitux R 57 Engerix B 57 lesinurad 57 immunogenicity 57 COPAXONE R 57 Fondaparinux 57 micafungin 57 subcutaneous enoxaparin 57 orally dosed 57 OHR/AVR# 57 interferon beta 1b 57 fluoroquinolone antibiotic 57 NP2 Enkephalin 57 AEG# 57 paclitaxel poliglumex 57 rhGH 57 #mg BID [003] 57 hA# 57 granisetron 57 erlotinib 57 blinded placebo controlled 57 metreleptin 57 CHOP chemotherapy 57 trans retinoic acid ATRA 57 prophylaxis 57 AVE# 57 metastatic renal cell carcinoma 57 candesartan 57 PEG Intron 57 palonosetron 57 trastuzumab Herceptin 57 deforolimus 57 Allovectin 7 R 57 Zileuton 57 multicenter Phase III 57 AzaSite Plus 57 Ribavirin 57 dasatinib Sprycel ® 57 muraglitazar 57 NXL# 57 BROVANA 57 rilonacept 57 evaluating REVLIMID 57 chemotherapy docetaxel 57 CRx 57 injectable formulations 57 NPH insulin 57 Phase III placebo controlled 57 oral NSAIDs 57 Capesaris 57 intravenous cyclophosphamide 57 antiplatelet agent 57 Pazopanib 57 torezolid phosphate 57 rapid virologic response 57 prophylactic treatment 57 postmenopausal osteoporotic women 57 microtubule inhibitor 57 adefovir dipivoxil 57 dexlansoprazole 57 Tyrima 56 concomitant medications 56 oral vancomycin 56 ganaxolone 56 steroid inhalers 56 relapsed MM 56 minocycline